AI
Back to basics: Agentic AI and how it’s impacting clinical trial research
Since the release of OpenAI’s ChatGPT in 2022, the buzz around artificial intelligence has been impossible to ignore. From advertisements during the SuperBowl to webinars and working groups, the impact of artificial intelligence has been felt in almost every sector of our world.
But, what if we told you the most transformative shift is still on the horizon?
When ChatGPT first released it changed the way the world, including clinical research, worked. Now NVIDIA, one of the most premier companies leading the way in the development of AI, has stated that they expect the development of Agentic AI, a new type of artificial intelligence to “change the way we work in ways that parallel how different work became with the arrival of the internet.”
This means agentic AI may have a much bigger impact than even generative AI did years back.
So, if you’re curious about agentic AI, read on as we delve into its nature, differentiate it from generative AI, and reveal its transformative role in clinical research."
Recapping DIA 2025
The 2025 Drug Information Association (DIA) Global Annual Meeting, held in Washington D.C., is beginning to wind down. As always, the conference has left a clear vision for the future of clinical trials. one defined by groundbreaking innovation, unprecedented global collaboration, and a profound commitment to patient well-being. This year's conference underscored key themes that are shaping the landscape of medical product development, with Artificial Intelligence (AI) and Real-World Data (RWD) taking center stage.